Acute Lymphoblastic Leukaemia

Allogeneic hematopoietic stem cell transplantation after CD19 chimeric antigen receptor T-cell therapy is thought to improve leukemia-free survival.

September is Childhood Cancer Awareness Month.

Adolescents and young adults with overweight or obesity had poorer clinical outcomes than their normal-weight counterparts after receiving a pediatric regimen for treatment of acute lymphoblastic leukemia, study results showed.

The FDA announced several regulatory actions the past few weeks.

A partnership between health care systems along the U.S.-Mexico border led to clinically meaningful improvement in survival outcomes among children with acute lymphoblastic leukemia, study results showed.

Children with acute lymphoblastic leukemia receiving maintenance therapy who lived in extreme poverty had nearly double the risk for relapse compared with children who did not live in extreme poverty, according to data published in Blood.

Brexucabtagene autoleucel continued to confer a greater than 70% complete remission rate among adults with relapsed or refractory B-cell acute lymphoblastic leukemia, results from the latest analysis of a pivotal phase 2 study showed.

This year’s ASH Annual Meeting and Exposition spotlighted practice-changing research in malignant and benign hematology.

Combining the tyrosine kinase inhibitor dasatinib with prednisone and blinatumomab seemed safe in older patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, researchers reported.

Inotuzumab ozogamicin was well tolerated among patients with acute lymphoblastic leukemia who had undergone allogenic transplantation in a small study.